Why did Quest raise revenue guidance but lower reported EPS guidance?

The revenue increase reflects strong demand and customer growth. The lower reported EPS range is driven by higher expected restructuring and integration charges (about $38 million pre-tax, versus prior expectations) and an estimated $12 million loss from contingent consideration fair value changes, which are excluded from adjusted EPS but reduce GAAP results.

Is Quest's underlying business growing?

Management reported nearly 6% base business revenue growth, but total reported revenue grew only 1.5%, largely because of the decline in COVID-related testing volumes from the prior year. Organic requisition volume grew 1.0%, while total requisition volume rose 1.6%, and revenue per requisition rose 0.1%.

Why did reported operating margin decline?

Reported operating margin fell to 12.7% from 13.1%, and adjusted operating margin declined to 14.8% from 15.0%. Drivers include higher interest expense (up to $43 million from $35 million on a net basis, though this sits below operating income), amortization of acquired intangibles rising to $29 million, and cost of services growing faster than revenue.

What should investors watch on the balance sheet?

Cash dropped to $474 million from $686 million after acquisitions and dividends. Current portion of long-term debt rose to $906 million from $303 million, so investors should watch how the company plans to refinance or repay these obligations within the next twelve months.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 23, 2024. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported first quarter 2024 results on April 23, 2024, showing modest top-line growth alongside flat-to-lower profitability.

Net revenues rose 1.5% year over year to $2.37 billion^a, the first year-over-year revenue increase since the pandemic peak, with management citing nearly 6% base business growth (excluding COVID-related testing and other items) and strong physician, hospital, and health plan demand. Reported diluted EPS fell 3.4% to $1.72, while adjusted diluted EPS was flat at $2.04. Operating margin contracted, with reported operating income down 1.7% to $300 million and adjusted operating margin declining 20 basis points to 14.8%.

Restructuring, amortization, and higher interest expense weighed on the bottom line; net interest expense rose to $43 million^b from $35 million. The company raised full-year 2024 guidance. Revenue is now expected at $9.40 to $9.48 billion (versus prior $9.35 to $9.45 billion), reported diluted EPS at $7.57 to $7.82 (up from $7.69 to $7.99 at the low and high ends respectively, so the range was actually lowered on the GAAP side), and adjusted diluted EPS at $8.72 to $8.97 (up from $8.60 to $8.90).

Investors should note that the reported EPS guidance was lowered despite the revenue raise, reflecting higher restructuring charges and amortization. Operating cash flow guidance of about $1.3 billion^c and capex of about $420 million were unchanged. Balance sheet and cash flow data show operating cash flow of $154 million, up 64.8%, with capital expenditures down 18.2% to $104 million.

Cash fell to $474 million^d from $686 million at year end, partly due to $142 million in acquisitions and $79 million in dividends. Total debt declined from roughly $4.7 billion to $4.7 billion, with a notable reclassification of $906 million to current portion of long-term debt, which investors should monitor for near-term refinancing needs.

02—Key points

Key Highlights

Q1 2024 net revenues of $2.37 billion, up 1.5% year over year; Diagnostic Information Services revenues up 1.7%
Management cited nearly 6% base business revenue growth and the first total revenue growth since the pandemic peak
Reported diluted EPS of $1.72, down 3.4%; adjusted diluted EPS flat at $2.04
Full-year 2024 revenue guidance raised to $9.40–$9.48 billion from $9.35–$9.45 billion
Reported diluted EPS guidance lowered to $7.57–$7.82 from $7.69–$7.99, while adjusted EPS guidance raised to $8.72–$8.97
Operating cash flow rose 64.8% to $154 million; capex fell 18.2% to $104 million
Cash declined to $474 million from $686 million, and $906 million of debt was reclassified to current liabilities

03—Questions

Frequently Asked Questions

Why did Quest raise revenue guidance but lower reported EPS guidance?
The revenue increase reflects strong demand and customer growth. The lower reported EPS range is driven by higher expected restructuring and integration charges (about $38 million pre-tax, versus prior expectations) and an estimated $12 million loss from contingent consideration fair value changes, which are excluded from adjusted EPS but reduce GAAP results.
Is Quest's underlying business growing?
Management reported nearly 6% base business revenue growth, but total reported revenue grew only 1.5%, largely because of the decline in COVID-related testing volumes from the prior year. Organic requisition volume grew 1.0%, while total requisition volume rose 1.6%, and revenue per requisition rose 0.1%.
Why did reported operating margin decline?
Reported operating margin fell to 12.7% from 13.1%, and adjusted operating margin declined to 14.8% from 15.0%. Drivers include higher interest expense (up to $43 million from $35 million on a net basis, though this sits below operating income), amortization of acquired intangibles rising to $29 million, and cost of services growing faster than revenue.
What should investors watch on the balance sheet?
Cash dropped to $474 million from $686 million after acquisitions and dividends. Current portion of long-term debt rose to $906 million from $303 million, so investors should watch how the company plans to refinance or repay these obligations within the next twelve months.

04—Continue

← View all 8-K filings